Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-cash Items: 2012-2024

Historic Non-cash Items for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Dec 2024 value amounting to $8.2 million.

  • Lineage Cell Therapeutics' Non-cash Items fell 21.05% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 21.05%. This contributed to the annual value of $8.2 million for FY2024, which is 683.19% up from last year.
  • Lineage Cell Therapeutics' Non-cash Items amounted to $8.2 million in FY2024, which was up 683.19% from $1.0 million recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-cash Items peaked at $9.6 million during FY2021, and registered a low of $8,341 during FY2020.
  • Its 3-year average for Non-cash Items is $6.0 million, with a median of $8.2 million in 2024.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Non-cash Items soared by 114,994.11% in 2021 and then plummeted by 88.18% in 2023.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Non-cash Items stood at $8,341 in 2020, then soared by 114,994.11% to $9.6 million in 2021, then decreased by 7.70% to $8.9 million in 2022, then slumped by 88.18% to $1.0 million in 2023, then spiked by 683.19% to $8.2 million in 2024.